Active Ingredient History

NOW
  • Now
Mycophenolic acid (MPA) possesses antibacterial, antifungal, antiviral, immunosuppressive and anticancer properties. Mycophenolic acid (MPA) is a fungal metabolite that was initially discovered by Bartolomeo Gosio in 1893 as an antibiotic against anthrax bacillus, Bacillus anthracis. It is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. It was approved under the brand name Myfortic for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant. Myfortic is to be used in combination with cyclosporine and corticosteroids.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$0.1865 - $106.3500

Australia

$0.3666 - $203.8264
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate | 68618 | acide mycophenolique | acido micofenolico | acidum mycophenolicum | arzip | cellcept | (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid | erl-080 | linfonex | micofenolico acido | mmf | myclausen | mycophenolate | mycophenolate mofetil | mycophenolate mofetil hcl | mycophenolate mofetil hydrochloride | mycophenolate sod | mycophenolate sodium | mycophenolic acid | mycophenolic acid monosodium salt | mycophenolic acid morpholinoethyl ester | mycophenolsäure | myfenax | myfortic | myforticmycophenolic acid | rs-61443 | rs-61443-190 | rs-61443 [as mofetil] | sodium mycophenolate

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue